Oxford Cannabinoid Technologies Holdings Plc

Last month, as a founder member of the Cannabinoid Research and Development Group (CRDG UK), we were proud to attend the launch of the Group’s inaugural report “Going for growth: Transforming the UK into the global leader in cannabinoid R&D”, at the Royal Society of Medicine in London. For us and our co-founders, the launch of CRDG UK represents a hugely significant moment in the UK’s longstanding and growing relationship with the #cannabinoid R&D sector. Read more below ⬇

As a founding member of the Cannabinoid Research and Development Group (CRDG UK) the Oxford Cannabinoid Technologies Holdings Plc team was delighted to attend the launch of its inaugural report called “Going for Growth: Transforming the UK into the Global Leader in Cannabinoid R&D” at the Royal Society of Medicine yesterday. Read more below ⬇

It was great to see our CEO, Clarissa Sowemimo-Coker, speak at HLTH Europe 2024 last month in a panel discussion on “Eighths and pains: The ongoing trials and tribulations of #cannabis in healthcare” alongside Finn Age Hänsel, Karan Wadhera, and Sarah Sinclair.   Clarissa discussed the important work Oxford Cannabinoid Technologies Holdings Plc is doing in the #cannabinoid R&D space and how we plan to bring help to people living with debilitating conditions through harnessing the therapeutic power of cannabinoids.   You can find the full recording of the panel below ⬇️   https://lnkd.in/ex6th6e2 Lina Behrens #OCTP #pain

Following a period of significant achievement over the last year, including entering our lead programme into the clinic and advancing our second programme to be clinic-ready, we’re looking to appoint an experienced Head of Drug Discovery and Development to join our team. Our new Head of Drug Discovery and Development will have responsibility for bringing pipeline assets into the clinic and prosecuting our therapeutic programmes to industry standards, with a particular focus on developing our proprietary library of 475 #cannabinoid derivatives, as well as providing both additional scientific expertise and further commercial focus. The ideal candidate should have: senior scientific/biological leadership gained from SME/biotech; a track record of successfully pursuing IND strategies and advancing candidate molecules for IND/CTA enabling studies; and an interest in the pain therapeutic area. An interest in oncology, rare diseases, and in cannabinoid therapeutics, would also be an advantage. For more information or to have a discussion about this role, please send your CV to peter.tucker@novoexec.com. #OCT #pain #cancer #cannabinoids #research #drugdevelopment

Last week, our CEO, Clarissa Sowemimo-Coker, attended and spoke at HLTH Europe 2024 in a panel discussion on “Eighths and pains: The ongoing trials and tribulations of #cannabis in healthcare”. At Oxford Cannabinoid Technologies Holdings Plc, we’re proud to play our part by supporting important events across our sector and meeting inspiring colleagues from across the #cannabinoid R&D space, as we work together to harness the therapeutic power of #cannabinoids to bring help to people living with debilitating conditions around the world. #OCTP #pain #cancer

Our CEO Clarissa Sowemimo-Coker is looking forward to speaking at HLTH Europe 2024 today in a panel discussion on “Eighths and pains: The ongoing trials and tribulations of #cannabis in healthcare”.   If you’re at HLTH Europe 2024, come and meet Clarissa Sowemimo-Coker at the Touch Stage at 15:30 CEST!

A strategic review of #OCTP's business has concluded that de-listing from the London Stock Exchange's Main Market best secures our drug development programmes and is in the long-term interests of #OCTP, its business and investors.   CEO Clarissa Sowemimo-Coker explains our rationale. ⬇️ https://lnkd.in/ejGWHAF5

In February, we announced the appointment of Lord Darren Mott OBE as an independent Non-Executive Director at Oxford Cannabinoid Technologies Holdings Plc. Today, Lord Mott shares his reflections on joining #OCTP's innovative journey at this important moment in its development as we move our second programme forward, into the clinic. Read more below ⬇️

Our #OCTP Chief Medical Officer, Tim Corn, spoke to StockBox to discuss the appointment of iNGENū CRO to conduct a Phase I #ClinicalTrial for our second programme, OCT130401. OCT130401 is a combination of synthetic phytocannabinoids (pCBs) and a medical device for the effective, safe, and non-addictive treatment of chronic and severe pain conditions. The initial target for OCT130401 is trigeminal neuralgia, which is a #ChronicPain condition that causes an excruciating, stabbing, electric shock-like facial pain. #TrigeminalNeuralgia has a fast and unexpected onset, making it difficult to treat and each episode may last only a few seconds, but some people will suffer multiple (up to 100) episodes during a single day. #cannabinoids Watch the full video below ⬇️ https://lnkd.in/eyKa-yu8

We are pleased to announce that Oxford Cannabinoid Technologies Holdings Plc has entered into agreement with iNGENū CRO to conduct a Phase I randomised, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability and pharmacokinetics of OCT130401. iNGENū is an Australia-based, globally focused contract research organisation (CRO) possessing extensive experience working in the cannabinoid pharmaceutical drug development and clinical research industry. OCT130401 is a combination of synthetic phytocannabinoids (pCBs) and a medical device for the effective, safe, and non-addictive treatment of chronic and severe pain conditions. The initial target for OCT130401 is trigeminal neuralgia (TN), which is a chronic pain condition that causes an excruciating, stabbing, electric shock-like facial pain. Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said: "I am pleased to announce that OCT has selected iNGENū as its CRO partner for our Phase I clinical trial for our second programme, OCT130401, targeting Trigeminal Neuralgia. iNGENū is a well-recognised CRO, with a specific expertise in cannabinoids and the Australia regime also affords a direct path to US FDA approval which is an important target for the Company. Today's appointment and our confirmation that clinical trials will begin in Q2 2024 demonstrate that OCT continues to hit its milestones and is making good progress." Dr Sud Agarwal, Chief Executive Officer of iNGENū, said: "We are delighted to be OCT's CRO partner in its first Australia-based clinical trial. Whilst many people are aware of the financial benefits of the Australian research regime, many are less aware of the world-class clinical research units and the favourable regulatory laws, allowing rapid study start-up. We look forward to kicking off this work, which is aiming to meet a significant unmet need for people living with Trigeminal Neuralgia." Read more below ⬇️ https://lnkd.in/eexvP9Fa